BBC3 — BCL2 Binding Component 3 (PUMA)
Overview
BBC3 (BCL2 Binding Component 3), also known as PUMA (p53 Upregulated Modulator of Apoptosis), is a critical pro-apoptotic BH3-only protein that plays a central role in regulating mitochondrial apoptosis. In neurons, PUMA is a key mediator of cell death in various neurodegenerative conditions including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [stroke](/diseases/stroke), and [traumatic brain injury](/diseases/traumatic-brain-injury).[@hao2015] Understanding PUMA's function provides insight into the mechanisms of neuronal loss and identifies potential therapeutic targets for neuroprotection.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">BBC3 / PUMA</th></tr>
<tr><td><b>Gene Symbol</b></td><td>BBC3</td></tr>
<tr><td><b>Full Name</b></td><td>BCL2 Binding Component 3</td></tr>
<tr><td><b>Alias</b></td><td>PUMA, JFY1, PUMA-JFY1</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>19q13.3</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[10024](https://www.ncbi.nlm.nih.gov/gene/10024)</td></tr>
<tr><td><b>OMIM ID</b></td><td>[605426](https://www.omim.org/entry/605426)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000100711</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9BXW1](https://www.uniprot.org/uniprotkb/Q9BXW1/entry)</td></tr>
<tr><td><b>Protein Length</b></td><td>193 amino acids</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">12 edges</a></td>
</tr>
</table>
</div>
Normal Function
Protein Structure and Classification
PUMA is a member of the BH3-only subgroup of the [Bcl-2 family](/genes/b[@youle2008]cl2-family). Unlike anti-apoptotic Bcl-2 proteins or pro-apoptotic Bax/Bak proteins, BH3-only proteins contain only the BH3 (Bcl-2 Homology 3) domain, which is essential for their pro-apoptotic function.
PUMA exists in two major isoforms:
- PUMA-α: Full-length protein with mitochondrial localization
- PUMA-β: Alternatively spliced variant with distinct N-terminus
BH3 Domain Function
The BH3 domain of PUMA is critical for its function:
- Direct activation: Can directly activate Bax/Bak to trigger mitochondrial outer membrane permeabilization (MOMP)
- Sensitization: Can displace activators from anti-apoptotic Bcl-2 proteins
- Binding: Interacts with all anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-xL, Mcl-1, etc.)
Cellular Functions
In normal cells, PUMA regulates:
Apoptosis initiation: Rapid response to apoptotic signals
DNA damage response: Mediates p53-dependent cell death
ER stress response: Participates in unfolded protein response
Development: Regulates developmental cell death in certain tissues
Tumor suppression: Prevents cancer developmentBasal Expression
Under normal conditions, PUMA expression is:
- Low in most tissues: Minimal basal expression
- Tissue-specific: Higher in certain cell types
- Strictly regulated: Multiple transcriptional and post-transcriptional controls
Regulation of PUMA Expression
p53-Dependent Regulation
PUMA is a direct transcriptional target of [p53](/genes/tp53):
Direct binding: p53 binds to two promoter elements
Transcriptional activation: Rapid induction following DNA damage
Cell cycle arrest: Coordinates with p21 for cell cycle arrest
Apoptosis execution: Directs cells toward deathp53-Independent Pathways
PUMA can also be activated independently of p53:
| Pathway | Trigger | Mechanism |
|---------|---------|-----------|
| p53-independent p53 | E2F1, NF-κB | Direct transcriptional activation |
| ER stress | CHOP, ATF4 | Transcriptional upregulation |
| Growth factor withdrawal | FOXO transcription factors | Pro-apoptotic signaling |
| Cytokines | TNF-α, Fas ligand | Death receptor signaling |
Post-Transcriptional Regulation
- mRNA stability: AU-rich elements in 3' UTR
- Translation control: Internal ribosome entry site (IRES)
- MicroRNA targeting: miR-25, miR-30 family members
Role in Neurodegeneration
Alzheimer's Disease
In AD, PUMA plays a multifaceted role in neuronal death:
Amyloid-Beta Toxicity
- Aβ exposure induces PUMA expression in neurons
- PUMA mediates mitochondrial dysfunction
- Contributes to synaptic loss
Tau Pathology
- Phosphorylated tau enhances PUMA expression
- PUMA in turn promotes tau aggregation
- Creates vicious cycle of neurodegeneration
Energy Failure
- PUMA contributes to mitochondrial complex inhibition
- Enhances ROS production
- Accelerates neuronal energy crisis
Key Findings from AD Research:
- Elevated PUMA in AD brain tissue
- Correlation with disease severity
- Therapeutic targeting shows neuroprotection
Parkinson's Disease
PUMA is critically involved in dopaminergic neuron death:
α-Synuclein Toxicity
- Mutant α-synuclein induces PUMA expression
- PUMA mediates mitochondrial fragmentation
- Contributes to Lewy body formation
Mitochondrial Dysfunction
- PUMA is elevated in PD models
- Mediates complex I inhibition effects
- Participates in mitophagy dysfunction
Key Findings from PD Research:
- PUMA knockout protects dopaminergic neurons
- Reduced MPTP toxicity in PUMA-deficient mice
- Therapeutic modulation shows promise
Stroke and Cerebral Ischemia
In ischemic brain injury:
Excitotoxicity
- Glutamate-induced PUMA expression
- Calcium overload triggers PUMA activation
- Contributes to infarct expansion
Reperfusion Injury
- Oxidative stress induces PUMA
- Contributes to delayed neuronal death
- Inflammation amplifies PUMA expression
Neuroprotection
- PUMA knockout reduces infarct size
- PUMA inhibitors show therapeutic potential
- Combined approaches targeting multiple pathways
Traumatic Brain Injury
Following TBI:
- Rapid PUMA induction in injured neurons
- Contributes to secondary injury cascade
- Inhibition improves functional outcomes
Amyotrophic Lateral Sclerosis (ALS)
In ALS motor neuron degeneration:
- Elevated PUMA in sporadic and familial ALS
- Mutant SOD1 triggers PUMA expression
- TDP-43 pathology associated with PUMA dysregulation
Neuroinflammation
PUMA interacts with inflammatory pathways:
- Microglial activation: PUMA in neurons affects microglia
- Cytokine effects: Pro-inflammatory cytokines induce PUMA
- Cross-talk: NF-κB and PUMA form regulatory loops
Mechanisms of Neuronal Death
Mitochondrial Apoptosis Pathway
PUMA triggers neuronal death through the mitochondrial pathway:
Mermaid diagram (expand to render)
Key Steps:
Signal transduction: Pro-apoptotic signals activate transcription factors
PUMA induction: Rapid upregulation of PUMA mRNA and protein
Mitochondrial targeting: PUMA translocates to mitochondria
Bax/Bak activation: Direct or indirect activation of effectors
MOMP: Release of cytochrome c and other pro-apoptotic factors
Caspase cascade: Activation of initiator and effector caspases
Cell death: Execution of apoptosisAdditional Mechanisms
PUMA links ER stress to apoptosis:
- CHOP upregulates PUMA during unfolded protein response
- Calcium release activates pro-apoptotic pathways
- Cross-talk between ER and mitochondria
Autophagy Interactions
Complex relationship with autophagy:
- PUMA can be degraded by autophagy
- Autophagy can be protective against PUMA
- Crosstalk determines cell fate
Regulation in Neurons
Anti-Apoptotic Protectors
Neurons express high levels of protective proteins:
| Protein | Role | Interaction with PUMA |
|---------|------|----------------------|
| Bcl-2 | Mitochondrial protection | Directly binds PUMA |
| Bcl-xL | Long-term survival | Sequesters PUMA |
| Mcl-1 | Neuronal maintenance | Neutralizes PUMA |
| Bcl-w | Development | Functional redundancy |
Neurotrophic Factor Protection
Growth factors regulate PUMA:
- BDNF: Suppresses PUMA expression
- GDNF: Reduces PUMA induction
- NGF: Blocks PUMA-mediated death
Activity-Dependent Regulation
Neuronal activity modulates PUMA:
- Synaptic activity suppresses PUMA
- Electrical activity is protective
- Disuse/upregulation triggers death
Therapeutic Targeting
Rationale for Targeting PUMA
PUMA is an attractive therapeutic target because:
Central mediator: Convergence point for multiple death pathways
Druggable interactions: BH3 mimetics already in development
Therapeutic window: Normal cells less dependent on PUMA
Temporal control: Acute vs chronic intervention possibilitiesTherapeutic Strategies
BH3 Mimetics
Small molecules that mimic BH3-only proteins:
- ATN-344: Direct PUMA targeting (preclinical)
- S63845: Mcl-1 inhibition releases PUMA (cancer trials)
- Navitoclax (ABT-263): Bcl-2/xL inhibition
Gene Therapy Approaches
- PUMA siRNA: Knockdown of PUMA expression
- Antisense oligonucleotides: Block PUMA translation
- CRISPR: Base editing of PUMA promoter
Modulation of Upstream Signals
- p53 inhibitors: Reduce PUMA transcription
- Kinase inhibitors: Block signal transduction
- Calcium channel blockers: Prevent calcium-induced PUMA
Challenges
- Tumor risk: PUMA is a tumor suppressor
- Bifunctional: Can be protective in some contexts
- Delivery: CNS drug delivery challenges
- Timing: Acute vs chronic disease treatment
Biomarker Potential
PUMA as a Biomarker
PUMA has biomarker potential in neurodegeneration:
Fluid Biomarkers
- Blood/CSF PUMA: Elevated in neurodegenerative diseases
- Correlation: Levels correlate with disease progression
- Specificity: More specific than general apoptosis markers
Tissue Biomarkers
- Postmortem brain: PUMA elevation in affected regions
- Animal models: Predicts neuronal vulnerability
- Therapeutic response: Reduced PUMA with treatment
Clinical Applications
- Diagnostic marker: Aid in differential diagnosis
- Prognostic indicator: Predict disease progression
- Therapeutic monitoring: Track treatment response
Apoptosis and Cell Death
- [Apoptosis Pathway](/mechanisms/apoptosis-neurodegeneration) — Apoptosis in neurodegeneration
- [Caspase Activation](/mechanisms/caspase-activation) — Caspase-dependent cell death
- [Bcl-2 Family](/genes/bcl2-family) — Apoptosis regulation
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Energy failure in neurodegeneration
- [TP53](/genes/tp53) — Tumor suppressor and apoptosis regulator
- [BAX](/genes/bax) — Pro-apoptotic effector
- [BCL2](/genes/bcl2) — Anti-apoptotic protector
- [NOXA](/genes/noxa) — Another BH3-only protein
- [Alzheimer's Disease](/diseases/alzheimers-disease) — AD and PUMA
- [Parkinson's Disease](/diseases/parkinsons-disease) — PD and PUMA
- [Stroke](/diseases/stroke) — Ischemic injury
- [ALS](/diseases/als) — Motor neuron disease
Therapeutic Approaches
- [Neuroprotection](/therapeutics/neuroprotection) — General neuroprotective strategies
- [Mitochondrial Therapies](/therapeutics/mitochondrial-protectors) — Energy-focused treatments
Research Directions
Current Understanding
- PUMA is a central mediator of neuronal apoptosis
- Multiple pathways converge on PUMA activation
- Therapeutic targeting shows promise in models
- Biomarker potential is being explored
Emerging Research Areas
- Combination therapies: PUMA + other targets
- Cell-type specificity: Neuron-specific approaches
- Temporal targeting: Acute intervention strategies
- Biomarker development: Clinical validation needed
Preclinical and Clinical Trials
- BH3 mimetics in neuroprotection models
- Gene silencing approaches in development
- Biomarker studies in patient cohorts
Key Publications
[Yu et al., PUMA mediates p53-induced apoptosis. Cancer Cell. 2004](https://pubmed.ncbi.nlm.nih.gov/14712206/)
[Elde et al., PUMA in neuronal apoptosis. Cell Death Differ. 2009](https://pubmed.ncbi.nlm.nih.gov/19366699/)
[Reeks et al., BH3-only proteins in neuronal death. Cell Mol Neurobiol. 2005](https://pubmed.ncbi.nlm.nih.gov/15832171/)
[Youle et al., Bcl-2 family apoptosis pathway. Cell. 2008](https://pubmed.ncbi.nlm.nih.gov/18846108/)
[Shibue et al., Non-canonical p53 activation of PUMA. Genes Dev. 2013](https://pubmed.ncbi.nlm.nih.gov/23211775/)
[Hao et al., PUMA in Alzheimer's disease. J Neurosci. 2015](https://pubmed.ncbi.nlm.nih.gov/25894085/)
[Uo et al., PUMA in Parkinson's disease. Cell Death Dis. 2013](https://pubmed.ncbi.nlm.nih.gov/23526720/)
[Gomez-Lazaro et al., PUMA and mitochondrial apoptosis. Cell Calcium. 2008](https://pubmed.ncbi.nlm.nih.gov/18593950/)
[Wan et al., PUMA is required for p53-mediated neurodegeneration. Cell Death Differ. 2008](https://pubmed.ncbi.nlm.nih.gov/18626005/)
[Jeong et al., p53 transcriptional activation of PUMA in neurons. J Biol Chem. 2007](https://pubmed.ncbi.nlm.nih.gov/17568779/)Cross-References
- [Apoptosis Pathway](/mechanisms/apoptosis-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [BCL2 Gene Family](/genes/bcl2-family)
- [Caspase Activation](/mechanisms/caspase-activation)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Stroke](/diseases/stroke)
- [Traumatic Brain Injury](/diseases/traumatic-brain-injury)
- [Neurodegeneration](/diseases/neurodegeneration)
External Links
- [NCBI Gene: BBC3](https://www.ncbi.nlm.nih.gov/gene/10024)
- [UniProt: BBC3](https://www.uniprot.org/uniprotkb/Q9BXW1/entry)
- [OMIM: BBC3](https://www.omim.org/entry/605426)
- [GeneCards: BBC3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=BBC3)
- [Ensembl: BBC3](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100711)
References
[Yu et al., PUMA mediates p53-induced apoptosis (2004)](https://pubmed.ncbi.nlm.nih.gov/14712206/)
[Elde et al., PUMA in neuronal apoptosis (2009)](https://pubmed.ncbi.nlm.nih.gov/19366699/)
[Reeks et al., BH3-only proteins in neuronal death (2005)](https://pubmed.ncbi.nlm.nih.gov/15832171/)
[Youle et al., Bcl-2 family apoptosis pathway (2008)](https://pubmed.ncbi.nlm.nih.gov/18846108/)
[Shibue et al., Non-canonical p53 activation of PUMA (2013)](https://pubmed.ncbi.nlm.nih.gov/23211775/)
[Hao et al., PUMA in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25894085/)
[Uo et al., PUMA in Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23526720/)
[Gomez-Lazaro et al., PUMA and mitochondrial apoptosis (2008)](https://pubmed.ncbi.nlm.nih.gov/18593950/)
[Wan et al., PUMA is required for p53-mediated neurodegeneration (2008)](https://pubmed.ncbi.nlm.nih.gov/18626005/)
[Jeong et al., p53 transcriptional activation of PUMA in neurons (2007)](https://pubmed.ncbi.nlm.nih.gov/17568779/)
[Hitomi et al., PUMA in cerebral ischemia (2008)](https://pubmed.ncbi.nlm.nih.gov/18566447/)
[Morrell et al., PUMA in traumatic brain injury (2013)](https://pubmed.ncbi.nlm.nih.gov/23826869/)
[Engler et al., PUMA in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33568814/)
[Liu et al., PUMA and neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29883675/)
[Gao et al., PUMA in retinal neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30760004/)
[Akhtar et al., Targeting PUMA for neuroprotection (2020)](https://pubmed.ncbi.nlm.nih.gov/32877950/)
[Inoue et al., PUMA and ER stress (2019)](https://pubmed.ncbi.nlm.nih.gov/31122215/)
[Cheng et al., PUMA in stroke therapy (2016)](https://pubmed.ncbi.nlm.nih.gov/26988930/)
[Sun et al., PUMA and autophagy crosstalk (2020)](https://pubmed.ncbi.nlm.nih.gov/32919442/)
[Levin et al., PUMA as biomarker in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35128546/)Pathway Diagram
The following diagram shows the key molecular relationships involving BBC3 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)